Vifor blasts FDA’s ‘reckless’ renaming of 4 drugs under the same molecule moniker

Outside of the FDA’s decision to add four-letter, meaningless suffixes on the end of nonproprietary names for biologics, the naming of pharmaceuticals has not been a controversial task in recent years. But in a new citizen petition filed earlier this month, Switzerland’s Vifor Pharma is raising concerns with the FDA’s…

Read the source article at endpts.com
2021-08-13 14:35:33